{"id":726149,"date":"2023-01-26T08:34:20","date_gmt":"2023-01-26T13:34:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/"},"modified":"2023-01-26T08:34:20","modified_gmt":"2023-01-26T13:34:20","slug":"sight-sciences-announces-1000th-tearcare-customer-installation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/","title":{"rendered":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation"},"content":{"rendered":"

\nOver 1,000 Professional Eye Care Practices Have integrated the TearCare\u00ae System\u00a0to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD)
\n<\/h2>\n
\n

MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients\u2019 lives, announced today the 1,000th<\/sup> installation of its TearCare\u00ae System. The TearCare\u00ae System is FDA cleared and indicated for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands.<\/p>\n

In 2019 Sight Sciences commercialized the TearCare\u00ae System with the knowledge that doctors, and patients were seeking improvements beyond those provided by current over the counter, prescription pharmaceutical, or in-office treatments for dry eye. Desired improvements included faster action, enduring results and, in the case of in-office treatment, a price point allowing more practices to equip their offices. Immediately following launch, Sight Sciences took the first step required to obtain access to coverage and payment for dry eye sufferers when the American Medical Association (AMA) granted a temporary procedural code specifically describing the open eye TearCare\u00ae procedure. In 2021, on the heels of publishing compelling signs and symptoms clinical results from its first large randomized controlled clinical trial (RCT), OLYMPIA, in the leading ocular surface journal Cornea, the company announced the initiation of its second pivotal RCT, the SAHARA study, intended to assist payors in providing fair patient access to the interventional TearCare dry eye procedure. Sahara is a large randomized controlled clinical trial designed to provide a robust body of evidence comparing the long-term efficacy of the TearCare\u00ae System to a traditional, daily, prescription pharmaceutical treatment regimen for dry eye. The company expects to begin readout and publishing of the data from SAHARA later this year and continuing into 2024. The company intends to use the data to support the case for appropriate coverage and payment by third party payers to help drive patient access to care for dry eye disease due to MGD.<\/p>\n

Total Eye Care of Long Island, N.Y., was the 1000TH practice to install the TearCare\u00ae System. Stephanie K. Becker, MD, CEO & noted dry eye specialist, commented that \u201cimpressive clinical study results, device footprint with a reasonable capital investment, along with Sight Sciences’ commitment to pursue appropriate insurance coverage and fair payment all combined in the decision to add the TearCare\u00ae System to our dry eye treatment armamentarium. We are pleased to offer TearCare\u00ae to indicated dry eye patients.\u201d<\/p>\n

\u201cWe are thrilled that over 1,000 eye care practices have chosen the TearCare\u00ae System to treat dry eye caused by MGD,\u201d said Paul Badawi, co-founder, and Chief Executive Officer of Sight Sciences. \u201cWe designed TearCare\u00ae to treat the underlying cause of MGD and restore production of healthy tears. The over 1,000 votes of confidence that we have received from eye doctors across the United States along with our outstanding clinical and real-world outcomes, demonstrate the increasing importance and acceptance of effective interventional dry eye treatment. We are particularly proud to have an ophthalmologist of Dr. Becker\u2019s clinical reputation and expertise represent this milestone occasion.\u201d<\/p>\n

\n About Sight Sciences<\/strong>
\n
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients\u2019 lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world\u2019s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company\u2019s OMNI\u00ae Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world\u2019s leading cause of irreversible blindness. The Company\u2019s TearCare\u00ae System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company\u2019s SION\u2122 Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.<\/p>\n

\n About the TearCare\u00ae System<\/strong>\n <\/p>\n

The TearCare\u00ae System is FDA cleared and indicated for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands. The TearCare\u00ae System is the only device designed to evacuate obstructed meibomian glands while harnessing a natural blink experience. The system is comprised of single-use, universally fitting SmartLids\u2122 which are placed on the eyelids to deliver \u201cintelligent therapeutic heat\u201d safely and effectively. The portable SmartHub\u2122 communicates directly with the SmartLids to precisely control the amount of phase transition heating and the duration of treatment. After 15 minutes of therapeutic heat, the Clearance Assistant forceps allows the ECP to control expression of the stagnant, obstructed meibum expertly and precisely by targeting individual meibomian glands while obtaining full visual confirmation of the success of this personalized treatment.
For more information, visit www.sightsciences.com<\/a>.<\/p>\n

OMNI\u00ae and TearCare\u00ae are registered trademarks of Sight Sciences.
SION\u2122 is a trademark of Sight Sciences.
\u00a9 2023 Sight Sciences. All rights reserved.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning status of the Company’s SAHARA clinical trial and anticipated timing and use of SAHARA clinical trial results. These statements often include words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201csuggests,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cestimates,\u201d \u201ctargets,\u201d \u201cprojects,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cforecast\u201d and other similar expressions. Management bases these forward-looking statements on its current expectations, plans and assumptions affecting the Company\u2019s business and industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. The forward-looking statements are subject to and involve risks, uncertainties and assumptions, and you should not place undue reliance on these forward-looking statements. Some of the risks and uncertainties that may cause actual results to materially differ from those expressed or implied by these forward-looking statements are discussed under the caption \u201cRisk Factors\u201d in the Company\u2019s filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.\u00a0\u00a0<\/p>\n

\n Media contact <\/strong>
\n
Hannah Jenkins
RHMM Inc.
pr@SightSciences.com<\/p>\n

\n Investor contact:<\/strong>
\n
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Over 1,000 Professional Eye Care Practices Have integrated the TearCare\u00ae System\u00a0to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients\u2019 lives, announced today the 1,000th installation of its TearCare\u00ae System. The TearCare\u00ae System is FDA cleared and indicated for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands. In 2019 Sight Sciences commercialized the TearCare\u00ae System with the knowledge that … <\/p>\n

Continue reading “Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-726149","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSight Sciences Announces 1,000th TearCare\u00ae Customer Installation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Over 1,000 Professional Eye Care Practices Have integrated the TearCare\u00ae System\u00a0to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients\u2019 lives, announced today the 1,000th installation of its TearCare\u00ae System. The TearCare\u00ae System is FDA cleared and indicated for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands. In 2019 Sight Sciences commercialized the TearCare\u00ae System with the knowledge that … Continue reading "Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-26T13:34:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc4OSM1MzcyNDM4IzIyMDk3NzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation\",\"datePublished\":\"2023-01-26T13:34:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/\"},\"wordCount\":1245,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTc4OSM1MzcyNDM4IzIyMDk3NzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/\",\"name\":\"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTc4OSM1MzcyNDM4IzIyMDk3NzE=\",\"datePublished\":\"2023-01-26T13:34:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTc4OSM1MzcyNDM4IzIyMDk3NzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTc4OSM1MzcyNDM4IzIyMDk3NzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sight-sciences-announces-1000th-tearcare-customer-installation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/","og_locale":"en_US","og_type":"article","og_title":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation - Market Newsdesk","og_description":"Over 1,000 Professional Eye Care Practices Have integrated the TearCare\u00ae System\u00a0to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients\u2019 lives, announced today the 1,000th installation of its TearCare\u00ae System. The TearCare\u00ae System is FDA cleared and indicated for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands. In 2019 Sight Sciences commercialized the TearCare\u00ae System with the knowledge that … Continue reading \"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-26T13:34:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc4OSM1MzcyNDM4IzIyMDk3NzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation","datePublished":"2023-01-26T13:34:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/"},"wordCount":1245,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc4OSM1MzcyNDM4IzIyMDk3NzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/","name":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc4OSM1MzcyNDM4IzIyMDk3NzE=","datePublished":"2023-01-26T13:34:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc4OSM1MzcyNDM4IzIyMDk3NzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc4OSM1MzcyNDM4IzIyMDk3NzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sight-sciences-announces-1000th-tearcare-customer-installation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sight Sciences Announces 1,000th TearCare\u00ae Customer Installation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=726149"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726149\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=726149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=726149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=726149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}